Hamill John P.'s Form 4 filing
Aprea Therapeutics, Inc. (APRE) · filed Oct 16, 2024
- Accession no.
- 0001104659-24-108962
- Filed
- Oct 16, 2024
- Trade date
- Oct 11, 2024
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $123. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hamill John P.CIK 0001716213 | Officer (SrVP/CFO/Prin Fin & Acct Ofcr) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 11, 2024 | Common Stock | PPurchaseAcquired | +50 | $2.46 | +$123 | 19,368 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.